Search Results for “FDA” – Page 177 – media

Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

Merck & Company is driving forward in its quest to develop a premier immuno-oncology pipeline. The company plunked down $394 million to acquire Australia-based Viralytics Ltd and its oncolytic immunotherapy treatments.
- Source: Biospace;
- 726
- February 26, 2018
immuno-oncology pipelin immunotherapy Market Views Merk
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Gilead Sciences, Inc.(NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available.
- Source: gilead
- 906
- February 26, 2018
Biktarvy FDA Gilead Sciences HIV-1 infection
Choices for Your Ideal Medical Hospital Beds

Nursing facilities and home- and community-based services are important for individuals' well-being and can often prevent the need for acute inpatient hospitalizations, which is why it’s important to choose suitable medical hospital beds. Ddu, the leading global pharmaceutical & medical device B2B online platform, now offers you some suggestions on how to choose your medical hospital beds.
- Source: Ddu
- 975
- February 26, 2018
Ddu College hospital beds
Priority review for Shire’s HAE drug

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).
- Source: pharmatimes
- 781
- February 24, 2018
angioedema HAE Market Views
Indian engineers build solar device to treat infant jaundice at home

Two Indian engineers have invented a portable photo-therapy device which allows parents treat jaundice within the comfort of their homes. The Neolight system is based on blue light-emitting diodes (LED) that can be used at home. It works on solar as well as battery power. The photo device can produce different wavelengths of light for the treatment of varying severities of infant jaundice.
- Source: greenubuntu
- 398
- February 24, 2018
jaundice Researches
Merck’s ERK inhibitor shows promise in combo against resistant cancers

One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of many cancers.
- Source: fiercebiotech
- 547
- February 23, 2018
cancer drugs Company Insight inhibitor
NICE sticks with ‘no’ for earlier use of Halaven

Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
- Source: pharmatimes
- 1,831
- February 23, 2018
breast cancer Market Views NHS
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS PROVIDES 2018 FINANCIAL GUIDANCE

Pfizer Inc. (NYSE: PFE) reported financial results for fourthquarter and full-year 2017 and provided 2018 financial guidance.
- Source: Pfizer
- 519
- February 21, 2018
Company Insight Pfizer
GSK delivers improvements in sales, margins and cash flow in 2017

GSK delivers improvements in sales, margins and cash flow in 2017：Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
- Source: GSK
- 494
- February 15, 2018
Company Insight GSK
Medical device product development– 7 pitfalls you need to avoid

Managing your medical device product development project can be a daunting task. There are regulations and paperwork to manage, along with expectations such as deadlines or goals for getting the device to market.
- Source: medicaldesignandoutsourcing
- 615
- February 14, 2018
Market Views medical device

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.